Evidence map›Paper›PMID 37139019›Full record

ArticleCureus2023

Feasibility of Using Ceftazidime-Avibactam as a Therapeutic Option for Bloodstream Infections Caused by Multidrug-Resistant Enterobacterales and Pseudomonas aeruginosa Based on Its Susceptibility Profile.

Ketan Priyadarshi, Sarumathi Dhandapani, Monika Sivaradjy, Lakshmi Shanmugam, Apurba S Sastry

Erratum issuedOpen access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Ketan PriyadarshiDepartment of Microbiology, All India Institute of Medical Sciences, Patna, IND.
Sarumathi DhandapaniDepartment of Microbiology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, IND.
Monika SivaradjyDepartment of Microbiology, Employees' State Insurance Corporation Medical College and Post Graduate Institute of Medical Science and Research, Chennai, IND.
Lakshmi ShanmugamDepartment of Microbiology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, IND.
Apurba S SastryDepartment of Microbiology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, IND.
Indira Gandhi Institute of Medical Sciences · INJawaharlal Institute of Post Graduate Medical Education and Research · INAll India Institute of Medical Sciences · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background In the era of increased antimicrobial resistance, there are limited therapeutic options available for the treatment of bacteremia caused by multidrug-resistant organisms (MDROs). This study aims to find out the feasibility of using ceftazidime/avibactam (CZA) as a therapeutic option for bloodstream infections caused by multidrug-resistant (MDR) Enterobacterales and

Indexed as

bloodstream infectionscarbapenem resistant organisms(cro)ceftazidime avibactamgram negative bacteremiamulti-drug resistant organisms (mdro)therapeutic choice

Identifiers

PMID37139019
PMCPMC10151155
OpenAlexW4362453358

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.